Barely Significant
← all excerpts

Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases.

Pharmaceuticals (Basel) · 2025 · PMC12736105 · PMID 41471389

Europe PMCDOI
1
hedged sentence
0.0400
closest p · 0.8× alpha
0.0400
boldest claim

The sentences

nominally significantp = 0.04actually significant
In the Phase 2 HART trial, the 45 mg bid (twice daily) dose showed a nominally significant benefit to TMS vs. placebo (Δ = −2.8, p = 0.04), particularly in hand movements (Δ = −0.93, p = 0.02) and gait and balance (Δ = −0.48, p = 0.04) [ 150 ].

also in 2,357 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.